ArticleParasites & vectors2025
Multiplex long-amplicon sequencing for comprehensive molecular surveillance of Plasmodium falciparum resistance to artemisinin and partner drugs in artemisinin-based combination therapies (ACTs).
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAntimalarial resistance, especially artemisinin resistance, in Plasmodium falciparum threatens global malaria control. Molecular surveillance of Plasmodium falciparum drug resistance is critical for monitoring the efficacy of artemisinin-based combination therapies (ACTs). Current molecular surveillance tools for Plasmodium falciparum artemisinin resistance are restricted to predefined polymorphism hotspots in limited loci (Pfk13 domain), failing to capture novel mutations in emerging resistance genes (Pfcoronin, Pfubp1, Pfap2μ) or cover complete coding regions. This study addresses this gap by developing an optimized long-amplicon panel for comprehensive, full-gene resistance surveillance.
methodsSix genes were selected for the multiplex PCR amplification, including four artemisinin resistance-related markers (Pfk13, Pfcoronin, Pfap2μ and Pfubp1) and two ACTs partner drugs resistance markers (Pfmdr1 and Pfcrt). Amplicons were standardized to 2.5 ± 0.2 kb using multiply software to minimize amplification bias. The full-length coverage of Pfk13, Pfcoronin and Pfap2μ was achieved. Primer concentrations and annealing temperatures were iteratively optimized through gel electrophoresis and sequencing validation. Analytical validation was assessed using 11 mock samples (parasitemia ranging from 1% to 0.0001%) and 16 field-collected venous blood (VB) samples. The samples were processed via Illumina paired-end sequencing.
resultsThe long-amplicon panel was specifically designed to cover the full-length coding region of the Pfk13 gene and co-amplify three artemisinin resistance-related molecular markers. It can exhibited species-specific amplification efficiency for Plasmodium falciparum targets with undetectable cross-reactivity against non-falciparum Plasmodium species. Analytical sensitivity thresholds were at 50 parasites/μL for dried blood spots (DBS) sample and 5 parasites/μL for VB sample, with all targets achieving 100% coverage. Notably, DBS samples over 50 p/μL required only 0.25GB of sequencing data (mean depth: 55 ×) for complete target coverage, while VB samples above 5 parasites /μL required 0.5GB data (mean depth: 33 ×) still keeping over 89% coverage uniformity. The total cost per sample was minimized to $15.60, encompassing PCR amplification, library preparation and sequencing.
conclusionsThe new long-amplicon panel improves malaria molecular drug-resistance monitoring by detecting known and emerging mutations across entire genes in a single test. The high sensitivity for ultralow parasitemia samples, coupled with their species specificity and cost-effectiveness, makes it a scalable tool for monitoring multidrug-resistant P. falciparum strains, particularly in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.